{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:07:27Z","timestamp":1772168847139,"version":"3.50.1"},"reference-count":44,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/X011100\/1"],"award-info":[{"award-number":["MR\/X011100\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Background Group B streptococcus (GBS) remains a leading cause of infant sepsis, meningitis and death despite intrapartum antibiotic prophylaxis. A vaccine is urgently required, and two candidates are in advanced clinical trials. For successful GBS vaccine implementation, especially if a vaccine is licensed based on an immunological threshold, there must be cross-sector engagement, effective advocacy, robust plans for phase IV studies and equitable access. Meeting A round-table discussion, held at St George\u2019s University of London, reviewed the current position of GBS vaccines in the UK context, focusing on phase IV plans, convening a diverse group of stakeholders from across the UK, with a role in GBS vaccine licensure, advocacy, implementation or effectiveness evaluation. Presentations outlined the latest UK epidemiology, noting the rising infant invasive GBS (iGBS) infection rates from 1996 to 2021 for both early and late onset disease, with the highest disease rates in Black infants (1.1\/1000 livebirths vs white infants (0.81\/1000 livebirths). Potential coverage of the candidate vaccines was high (&gt;95%). Regulatory input suggested that EU regulators would consider waiving the need for a pre-licensure efficacy study if a putative correlate of protection could be adequately justified. Phase IV study methodologies for a GBS vaccine were considered, largely based on previous UK maternal vaccine assessments, such as a nationwide cohort study design using a vaccine register and a maternal services dataset. Other strategies were also discussed such as a cluster or stepped-wedge randomised trial to evaluate implementation outcomes. Opportunities for advocacy, education and engagement with additional key partners were discussed and identified. Conclusions With an approved GBS vaccine a near possibility, planning of phase IV studies and identification of critical barriers to implementation are urgently needed. Cross-sector engagement is essential and will facilitate a successful pathway.<\/ns3:p>","DOI":"10.12688\/f1000research.147555.1","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T06:25:06Z","timestamp":1716272706000},"page":"519","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["GBS vaccines in the UK: a round table discussion"],"prefix":"10.12688","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-7677","authenticated-orcid":false,"given":"Natasha","family":"Thorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-5691","authenticated-orcid":false,"given":"Rebecca L","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Karampatsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mair","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate F","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Plumb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Greening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Eccleston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Rush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Sharkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1787-9025","authenticated-orcid":false,"given":"Lauren","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-7433","authenticated-orcid":false,"given":"Paul","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-085X","authenticated-orcid":false,"given":"Kirsty","family":"Le Doare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e807-e819","DOI":"10.1016\/S2214-109X(22)00093-6","article-title":"Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden.","volume":"10","author":"B Gon\u00e7alves","year":"2022","journal-title":"Lancet Glob. Health."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S200-S219","DOI":"10.1093\/cid\/cix664","article-title":"Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.","volume":"65","author":"A Seale","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"21-47","DOI":"10.1128\/CMR.00031-13","article-title":"Early-onset neonatal sepsis.","volume":"27","author":"K Simonsen","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e150-e157","DOI":"10.1093\/cid\/ciu514","article-title":"Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance.","volume":"59","author":"I Okike","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"D3-D6","DOI":"10.1016\/j.vaccine.2013.02.030","article-title":"The spectrum of perinatal group B streptococcal disease.","volume":"31","author":"C Baker","year":"2013","journal-title":"Vaccine."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S190-S199","DOI":"10.1093\/cid\/cix663","article-title":"Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-analyses.","volume":"65","author":"M Kohli-Lynch","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e8-e15","DOI":"10.1542\/peds.2011-3453","article-title":"Long-term outcomes of group B streptococcal meningitis.","volume":"130","author":"R Libster","year":"2012","journal-title":"Pediatrics."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"S100-S111","DOI":"10.1093\/cid\/cix658","article-title":"Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses.","volume":"65","author":"N Russell","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"S133-S142","DOI":"10.1093\/cid\/cix661","article-title":"Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-analyses.","volume":"65","author":"F Bianchi-Jassir","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"233-240","DOI":"10.1111\/1471-0528.16852","article-title":"Assessing the added value of group B Streptococcus maternal immunisation in preventing maternal infection and fetal harm: population surveillance study.","volume":"129","author":"T Lamagni","year":"2022","journal-title":"BJOG."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S125-S132","DOI":"10.1093\/cid\/cix585","article-title":"Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses.","volume":"65","author":"A Seale","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1437-1445","DOI":"10.1111\/1471-0528.13527","article-title":"Maternal group B Streptococcus-related stillbirth: a systematic review.","volume":"122","author":"C Nan","year":"2015","journal-title":"BJOG."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"224-233","DOI":"10.1001\/jamapediatrics.2018.4826","article-title":"Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance.","volume":"173","author":"S Nanduri","year":"2019","journal-title":"JAMA Pediatr."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"83-90","DOI":"10.1016\/S1473-3099(18)30555-3","article-title":"Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014-15: a prospective surveillance study.","volume":"19","author":"C O\u2019Sullivan","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"479-488","DOI":"10.1001\/jamainternmed.2018.7269","article-title":"Epidemiology of Invasive Group B Streptococcal Infections Among Nonpregnant Adults in the United States, 2008-2016.","volume":"179","author":"L Francois Watkins","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref16","article-title":"Laboratory surveillance of pyogenic and non-pyogenic streptococcal bacteraemia in England: 2021 update.","volume":"16","year":"2021"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"201-208","DOI":"10.1136\/archdischild-2018-316659","article-title":"Effect of intrapartum antibiotics on the intestinal microbiota of infants: a systematic review.","volume":"105","author":"P Zimmermann","year":"2020","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref18","article-title":"A PHASE 1\/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS.","year":"2023"},{"key":"ref19","article-title":"A Multicentre, Multinational, Parallel Group, Observer-Blind, Randomised, Placebo-Controlled Study on the Group B Streptococcus Vaccine (GBS-NN\/NN2), Investigating the Immunogenicity and Safety of Four Vaccination Regimens in Pregnant Woman, Assessing IgG Specific to AlpN Proteins in Cord Blood and Maternal Blood, and the Safety Profile in Mother and Infant up to 6 Months Post-Delivery.","year":"2023"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e1004068","DOI":"10.1371\/journal.pmed.1004068","article-title":"Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness.","volume":"20","author":"S Procter","year":"2023","journal-title":"PLoS Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S72-S76","DOI":"10.1097\/INF.0000000000002328","article-title":"Group B Streptococcus: Trials and Tribulations.","volume":"38","author":"H Davies","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"D52-D57","DOI":"10.1016\/j.vaccine.2013.02.029","article-title":"Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.","volume":"31","author":"S Madhi","year":"2013","journal-title":"Vaccine."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3190-3198","DOI":"10.1016\/j.vaccine.2019.04.039","article-title":"The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.","volume":"37","author":"J Vekemans","year":"2019","journal-title":"Vaccine."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1263-1272","DOI":"10.2147\/IDR.S203454","article-title":"A Vaccine Against Group B Streptococcus: Recent Advances.","volume":"13","author":"C Carreras-Abad","year":"2020","journal-title":"IDrugs."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.12688\/f1000research.9363.1","article-title":"Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.","volume":"5","author":"M Kobayashi","year":"2016","journal-title":"F1000Res."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"7033-7042","DOI":"10.1016\/j.vaccine.2018.09.058","article-title":"Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study.","volume":"36","author":"K Giorgakoudi","year":"2018","journal-title":"Vaccine."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e014634","DOI":"10.1136\/bmjopen-2016-014634","article-title":"Outcome of a screening programme for the prevention of neonatal invasive early-onset group B Streptococcus infection in a UK maternity unit: an observational study.","volume":"7","author":"G Rao","year":"2017","journal-title":"BMJ Open."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"236.e1-236.e14","DOI":"10.1016\/j.ajog.2021.08.007","article-title":"COVID-19 vaccination during pregnancy: coverage and safety.","volume":"226","author":"H Blakeway","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41467-023-36125-8","article-title":"National surveillance data analysis of COVID-19 vaccine uptake in England by women of reproductive age.","volume":"14","author":"L Magee","year":"2023","journal-title":"Nat. Commun."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"263-274","DOI":"10.1016\/S1473-3099(20)30478-3","article-title":"Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1\/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.","volume":"21","author":"J Absalon","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"21-30","DOI":"10.1016\/j.eclinm.2019.06.010","article-title":"The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses.","volume":"13","author":"P Zimmermann","year":"2019","journal-title":"EClinicalMedicine."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"142-150","DOI":"10.1086\/314574","article-title":"Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.","volume":"179","author":"C Baker","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"883-887","DOI":"10.1093\/infdis\/162.4.883","article-title":"Prevalence of anti-group B streptococcal type III capsular IgG antibodies in the United Kingdom and an analysis of their specific IgG subclasses.","volume":"162","author":"R Feldman","year":"1990","journal-title":"J. Infect. Dis."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"746-753","DOI":"10.1093\/cid\/ciw377","article-title":"The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.","volume":"63","author":"M Fabbrini","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"781-788","DOI":"10.1093\/infdis\/jit549","article-title":"Maternal antibody at delivery protects neonates from early onset group B streptococcal disease.","volume":"209","author":"C Baker","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1679-1683","DOI":"10.1016\/j.vaccine.2023.01.071","article-title":"Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.","volume":"41","author":"Z Dangor","year":"2023","journal-title":"Vaccine."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"570-577","DOI":"10.1093\/pubmed\/fds109","article-title":"Midwives\u2019 influenza vaccine uptake and their views on vaccination of pregnant women.","volume":"35","author":"D Ishola","year":"2013","journal-title":"J. Public Health (Oxf.)."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"504-512","DOI":"10.1038\/s41591-021-01666-2","article-title":"SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.","volume":"28","author":"S Stock","year":"2022","journal-title":"Nat. Med."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2775-2782","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.","volume":"388","author":"S Parikh","year":"2016","journal-title":"Lancet."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e1661-e1668","DOI":"10.1093\/cid\/ciaa1244","article-title":"First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England.","volume":"73","author":"S Ladhani","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S236-S243","DOI":"10.1093\/cid\/ciw559","article-title":"Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction.","volume":"63","author":"G Amirthalingam","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.07.23290978","article-title":"Vaccine effectiveness against mild and severe disease in pregnant mothers and their infants in England.","author":"F Kirsebom","year":"June 10, 2023"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.09.23296737","article-title":"Covid-19 vaccine safety in pregnancy, a nested case-control study in births from April 2021 to March 2022, England.","author":"A Mensah","year":"October 9, 2023"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e28435","DOI":"10.1371\/journal.pone.0028435","article-title":"Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales.","volume":"6","author":"N Andrews","year":"2011","journal-title":"PLoS One."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/13-519\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-519\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-519\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T08:05:18Z","timestamp":1724745918000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/13-519\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":44,"URL":"https:\/\/doi.org\/10.12688\/f1000research.147555.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.161761.r315656","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.161761.r304243","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.161761.r304243","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.161761.r315656","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.161761.r315651","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.161761.r315650","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/13-519\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.161761.r304243, Jennifer Gaddy, Vanderbilt University, Nashville, Tennessee, 07 Aug 2024, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/13-519\/v1#referee-response-304243","order":0,"name":"referee-response-304243","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Natasha Thorn<\/b>; \n<i>Posted: 12 Aug 2024<\/i>; Thank you for this helpful and insightful peer-review. We appreciate your time and positive comments on our manuscript.&nbsp;  We will certainly address your two points of suggestion. Thank you for highlighting the typographical error in point 2.&nbsp;  Regarding discussion of AMR in the article, in addition to paragraph 5 of the &quot;Epidemiology and surveillance&quot; section, we will include some additional context in the manuscript on penicillin hypersensitivity to further highlight the impact of clindamycin resistance.&nbsp;  We are awaiting a second peer review and will then make the above changes to the manuscript.&nbsp;","URL":"https:\/\/f1000research.com\/articles\/13-519\/v1#referee-comment-12207","order":1,"name":"referee-comment-12207","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.161761.r315656, Lisa Hanson, Marquette University, Milwaukee, 27 Aug 2024, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/13-519\/v1#referee-response-315656","order":2,"name":"referee-response-315656","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"UKRI Future Leaders Fellowship, awarded to Prof. Kirsty Le Doare (St George\u2019s University, London), Grant Ref: MR\/X011100\/1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}